Enko Dietmar, Zelzer Sieglinde, Niedrist Tobias, Holasek Sandra, Baranyi Andreas, Schnedl Wolfgang J, Herrmann Markus, Meinitzer Andreas
Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria.
Institute of Clinical Chemistry and Laboratory Medicine, General Hospital Hochsteiermark, Leoben, Austria.
EXCLI J. 2020 Sep 9;19:1275-1281. doi: 10.17179/excli2020-2763. eCollection 2020.
Recently, the microbiome-derived trimethylamine-N-oxide (TMAO) was shown to be present in human cerebrospinal fluid (CSF). However, data on the potential of TMAO crossing the blood-CSF barrier are still lacking. This retrospective study aimed at investigating possible associations between the CSF/serum albumin (Q) and TMAO (Q) quotient and evaluating Q values in individuals with and without blood-CSF barrier dysfunction. A total of 290 patients, who underwent diagnostic lumbar puncture with Q and Q determination, were evaluated. Serum and CSF TMAO measurements were performed on a tandem mass spectrometry SCIEX QTRAP 4500 (Applied Biosystems, Framingham, MA, USA) coupled with an Agilent 1260 Infinity HPLC system (Agilent Technologies Santa Clara, CA, USA). Serum and CSF albumin were measured on the Atellica NEPH 630 system (Siemens Healthineers, Erlangen, Germany). CSF TMAO levels were positively correlated with serum TMAO levels (ρ = 0.709, p < 0.001). The Q was significantly associated with the Q (ß-coefficient = 0.312; p < 0.001). A total of 117 patients with blood-CSF barrier dysfunction had significantly higher median (Q1 - Q3) Q values (4.7 (2.8 - 7.5) vs. 3.8 (2.5 - 5.7) x 10, p = 0.002) compared to 173 individuals with normal blood-CSF barrier function. CSF and serum TMAO concentrations were significantly associated in 290 CSF/serum pairs from lumbar punctures of clinical routine. Q showed a relevant influence on Q. Present results indicate that TMAO may cross the blood-CSF barrier.
最近，微生物群衍生的氧化三甲胺（TMAO）被证明存在于人体脑脊液（CSF）中。然而，关于TMAO穿越血脑屏障可能性的数据仍然缺乏。这项回顾性研究旨在调查脑脊液/血清白蛋白（Q）与TMAO（Q）比值之间的可能关联，并评估有和没有血脑屏障功能障碍的个体的Q值。总共评估了290例接受诊断性腰椎穿刺并测定Q和Q值的患者。血清和脑脊液TMAO测量在与安捷伦1260 Infinity高效液相色谱系统（美国加利福尼亚州圣克拉拉市安捷伦科技公司）联用的串联质谱SCIEX QTRAP 4500（美国马萨诸塞州弗雷明汉市应用生物系统公司）上进行。血清和脑脊液白蛋白在Atellica NEPH 630系统（德国埃尔兰根市西门子医疗公司）上测量。脑脊液TMAO水平与血清TMAO水平呈正相关（ρ = 0.709，p < 0.001）。Q与Q显著相关（β系数 = 0.312；p < 0.001）。与173例血脑屏障功能正常的个体相比，117例血脑屏障功能障碍患者的中位数（Q1 - Q3）Q值显著更高（4.7（2.8 - 7.5）对3.8（2.5 - 5.7）×10，p = 0.002）。在临床常规腰椎穿刺的290对脑脊液/血清样本中，脑脊液和血清TMAO浓度显著相关。Q对Q有显著影响。目前的结果表明TMAO可能穿越血脑屏障。
